GlassScriptPhysician profile
Matthew A Peters
NPI 1043312572
$3,030.43
in general payments reported to CMS, 2019-2025
22 companies · $826 in 2025
The $826 reported for 2025 was more than what 77% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $361 · 2022: $490 · 2023: $697 · 2024: $657 · 2025: $826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,164 · Education: $15.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,164.41 |
| Education | $15.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $579.50 | 2023-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $400.25 | 2021-2025 | Farxiga |
| Travere Therapeutics, INC. | $276.12 | 2022-2025 | Filspari |
| Fresenius USA Marketing, INC. | $218.98 | 2022-2024 | Velphoro, Korsuva |
| Aurinia Pharma U.S., INC. | $186.37 | 2021-2025 | Lupkynis |
| Ardelyx, INC. | $178.75 | 2024-2025 | Ibsrela |
| Amgen INC. | $162.38 | 2021-2025 | Tavneos |
| Mallinckrodt Hospital Products INC. | $153.56 | 2021-2025 | Acthar |
| Calliditas Therapeutics US INC. | $149.20 | 2022-2025 | Tarpeyo |
| Intuitive Surgical, INC. | $114.47 | 2023 | Da Vinci Surgical System |
| Bayer Healthcare Pharmaceuticals INC. | $97.67 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $93.57 | 2023-2025 | Ultomiris |
| Vifor Pharma, INC. | $91.86 | 2021-2024 | Veltassa |
| Glaxosmithkline, LLC. | $89.60 | 2022-2023 | Benlysta |
| Opko Pharmaceuticals, LLC | $78.65 | 2021-2023 | Rayaldee |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $28.10 | 2024 | |
| Merck Sharp & Dohme LLC | $26.21 | 2025 | Prevymis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.73 | 2025 | Jardiance |
| Akebia Therapeutics INC | $24.27 | 2021 | |
| Renalytix Ai, INC. | $20.12 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $18.74 | 2023 | Inpefa |
| Amicus Therapeutics, INC. | $17.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Peters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.